Enterprise Value

849.5M

Cash

275.3M

Avg Qtr Burn

-54.6M

Short % of Float

11.39%

Insider Ownership

8.08%

Institutional Own.

90.32%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
RGX-121 Details
Mucopolysaccharidosis type II, Rare diseases, Lung disease, Pulmonary arterial hypertension, Genetic disorder, Rare genetic disease, Mucopolysaccharidoses

BLA

Submission

ABBV-RGX-314 (Suprachoroidal Delivery) Details
Eye disease , Age-related macular degeneration, Wet age-related macular degeneration

Phase 2

Data readout

ABBV-RGX-314 (Suprachoroidal Delivery) Details
Diabetes, Eye disease , Diabetic retinopathy

Phase 2

Data readout

ABBV-RGX-314 (Subretinal Delivery) Details
Eye disease , Wet age-related macular degeneration , Age-related macular degeneration

Phase 2

Data readout

RGX-381 Details
Central nervous system illness

Phase 1/2

Data readout

RGX-202 Details
Genetic disorder, Rare diseases, Rare genetic disease, Duchenne muscular dystrophy

Phase 1/2

Data readout

RGX-111 Details
Mucopolysaccharidoses, Rare genetic disease, Genetic disorder, Rare diseases, Mucopolysaccharidosis Type 1

Phase 1/2

Update

RGX-181 Details
Central nervous system illness, Batten Disease

Phase 1

Data readout